264 related articles for article (PubMed ID: 10872643)
1. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
[TBL] [Abstract][Full Text] [Related]
2. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
4. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Jorga K; Fotteler B; Banken L; Snell P; Steimer JL
Br J Clin Pharmacol; 2000 Jan; 49(1):39-48. PubMed ID: 10606836
[TBL] [Abstract][Full Text] [Related]
6. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Gasser UE; Jorga K; Crevoisier C; Hovens SE; van Giersbergen PL
Eur Neurol; 1999; 41(4):206-11. PubMed ID: 10343151
[TBL] [Abstract][Full Text] [Related]
7. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
Guay DR
Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
Baas H; Zehrden F; Selzer R; Kohnen R; Loetsch J; Harder S
Clin Pharmacokinet; 2001; 40(5):383-93. PubMed ID: 11432539
[TBL] [Abstract][Full Text] [Related]
9. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
[TBL] [Abstract][Full Text] [Related]
10. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
[TBL] [Abstract][Full Text] [Related]
11. Tolcapone increases maximum concentration of levodopa.
Müller T; Woitalla D; Schulz D; Peters S; Kuhn W; Przuntek H
J Neural Transm (Vienna); 2000; 107(1):113-9. PubMed ID: 10809409
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
Jorga KM
Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
[TBL] [Abstract][Full Text] [Related]
13. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
14. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
16. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
[TBL] [Abstract][Full Text] [Related]
17. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE
Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768
[TBL] [Abstract][Full Text] [Related]
18. Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.
Jorga KM; Davis TL; Kurth MC; Saint-Hilaire MH; LeWitt PA; Fotteler B; Zürcher G; Rabbia M
Clin Neuropharmacol; 2000; 23(2):98-105. PubMed ID: 10803800
[TBL] [Abstract][Full Text] [Related]
19. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
Kurth MC; Adler CH; Hilaire MS; Singer C; Waters C; LeWitt P; Chernik DA; Dorflinger EE; Yoo K
Neurology; 1997 Jan; 48(1):81-7. PubMed ID: 9008498
[TBL] [Abstract][Full Text] [Related]
20. Tolcapone for Parkinson's disease.
Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124
[No Abstract] [Full Text] [Related]
[Next] [New Search]